Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia

Haemophilia

Volumn 6, Issue 2, 2000, Pages 98-103

  Ragni, M V ^a,f   Lusher, J M ^b   Koerper, M A ^c   Manco Johnson, M ^d   Krause, D S ^e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Mt States Reg Haemophilia Center   (United States)

^e SmithKline Beecham   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anti HAV; Haemophilia; Hepatitis A virus; Immunogenicity; Safety; Vaccination

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS A VACCINE; IMMUNOGLOBULIN G;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HEMOPHILIA; HEPATITIS A; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; PHASE 4 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROCONVERSION; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CONSUMER PRODUCT SAFETY; CONTUSIONS; ERYTHEMA; FACTOR VIII; FEMALE; FEVER; HEADACHE; HEPATITIS A VACCINES; HEPATITIS ANTIBODIES; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; INFLAMMATION; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; ISOANTIBODIES; MALE; PAIN; PROSPECTIVE STUDIES; THERAPEUTIC EQUIVALENCY; TIME FACTORS; VIRAL HEPATITIS VACCINES;

EID: 0034106762     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2000.00386.x     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Wkly Rep 1996; 45 (RR-15): 1-30.
2. Margolis HS, Alter MJ. Will hepatitis A become a vaccine-preventable disease? Ann Int Med 1995; 122: 464-5.
3. Mannucci PM, Gdovin A, Gringeri A et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Int Med 1994; 120: 1-7.
4. Normann A, Graff H, Gerritzen A, Brackman H, Fleming B. Detection of hepatitis A virus RNA in commercially available factor VIII preparations. Lancet 1992; 340: 1232-3.
5. Scaraggi FA, Perricci A, Petronelli M et al. Prevalence of serum IgG antibodies to hepatitis A virus in Italian hemophiliacs. Lancet 1992; 339: 1486-7.
6. Nowicki MJ, Mosley JW, Koerper MA et al. Passive antibody to hepatitis A virus in U.S. hemophiliacs. Lancet 1993; 341: 562.
7. Kreuz W, Klarmann D, Auerswald G et al. Absence of hepatitis A after treatment with pasteurized factor VIII concentrates in children with hemophilia A and von Willebrand disease. Lancet 1993; 341: 446.
8. Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 1328-34.
9. Medical and Scientific Advisory Committee. National Hemophilia Foundation Medical Bulletin 1995; 226.
10. Santagostino E, Gringeri A, Rocino A, Zanetti A, de Biasi R, Mannucci PM. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemostas 1994; 72: 508-10.
11. Rothschild C, Pol S, Mattlinger B, Reijasse D, Torchet MF, Gazengel C. Vaccination against hepatitis A infection in French hemophilic children. Vox Sang 1995; 69: 80-1.
12. Dentico P, Ciavarella N, Scaraggi FA et al. Long-term immunogenicity and safety of an inactivated hepatitis A vaccine in haemophilic patients. Haemophilia 1996; 2: 37-40.
13. Zuckerman JN, Moore S, Smith H, Tyrrell H, Baxter A, Lee CA. A study to assess the immunogenicity, reactogenicity, and safety of hepatitis A vaccine administered subcutaneously to patients with congenital disorders. Haemophilia 1996; 2: 235-9.
14. Berger R, Just M, Althaus B. Time course of hepatitis A antibody production after active, passive, and active/ passive immunisation: the results are highly dependent on the antibody test system used. J Virolog Methods 1993; 43: 287-98.
15. Ragni MV, Ruben FL, Winkelstein A, Spero JA, Bontempo FA, Lewis JH. Antibody response to immunization of patients with hemophilia with and without evidence of HIV (HTLV-III) infection. J Lab Clin Med 1987; 109: 545-9.
16. Pasi KJ, Evans JA, Wadhwa M, Thorpe R, Hill FG. Association of changes in monocyte antigen presentation and cytokine production in haemophilic boys with treatment and blood-borne virus infection. Br J Haematol 1995; 91: 191-6.
17. Weimer R, Zipperle S, Daniel V, Opelz G. In vitro cytokine treatment of B cell defects in HIV-infected haemophilia patients. Vox Sanguinis 1995; 69: 27-37.
18. Schogl D, Zimmerman K, Turecek PL, Schwarz HP, Eibl MM, Mannhalter JW. Effect of high-versus intermediate-purity blood coagulation factor concentrates on HIV-1 replication. Vox Sanguinis 1996; 70: 195-7.
19. Wertzberger A, Mensch B, Kuter B et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327: 453-7.
20. Troisi CL, Hollinger FB, Krause DS, Pickering LK. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX®; SKB): a comparative study of two dosing schedules. Vaccine 1997; 15: 1613-7.